Other Issues:

AIDScience Perspectives: Barebacking and bug chasers: expressions of an HIV subculture. Another wrinkle to the developing debate on the risks, consequences and value of an only partially effective future HIV vaccine. By Marcia Trinfol. [Free full text article] [About AIDScience articles] [See recent AIDScience articles] [dEbates: Submit a response to this article]

From Science: Vaccine results lose significance under scrutiny. Few would have predicted the confusion that ensued when VaxGen released its long-awaited findings on 24 February. Over the next few days, VaxGen officials contradicted each other about how the data were analyzed and reported and whether some of the conclusions are statistically significant. By Jon Cohen. [Free full text article] [About AIDScience articles] [See recent AIDScience articles] [dEbates: Submit a response to this article]

Hot News: From Medscape: Unsurprising and surprising results of VaxGen's HIV vaccine trial. An expert interview with Mark Feinberg, medical director of the Hope Clinic at the Emory Vaccine Research Center in Atlanta, Georgia. [Read paper] (one-time registration required)

Expert panel does not believe unsafe injections spread HIV in Africa. An expert group hosted by WHO/UNAIDS has reaffirmed that unsafe sexual practices are responsible for the vast majority of HIV infections in sub-Saharan Africa, not unsafe medical injection practices. [WHO/UNAIDS release]

U.S. FDA approves Fuzeon. The first drug to block entry of HIV into immune cells provides new hope, but expected cost to be three times higher than most expensive current treatments. [Trimeris press release] [Report] [New England Journal of Medicine report]

Satellite broadcast on HIV prevention. The U.S. CDC and the Public Health Training Network will present a satellite broadcast and web cast on rapid tests for HIV. Morbidity and Mortality Weekly Report [More...]

From Medscape: Candidate HIV/AIDS vaccines: Lessons learned from the world's first phase III efficacy trials The North American/European trial will determined the efficacy of AIDSVAX B/B, a bivalent subtype B gp120 vaccine using MN and GNE8 antigens. The Thailand trial will determine the efficacy of AIDSVAX B/E, a bivalent gp120 vaccine containing the MN and A244 envelope antigens from subtype B and subtype E viruses respectively, against blood-borne infection. AIDS 17(2), 147, 2003 [Read paper] (one-time registration required)

ADODB.Connection error '800a0e7a'

Provider cannot be found. It may not be properly installed.

/Issues/Issue046.asp, line 100